JonesTrading Initiates Coverage On CalciMedica with Buy Rating, Announces Price Target of $22
Portfolio Pulse from Benzinga Newsdesk
JonesTrading analyst Catherine Novack initiates coverage on CalciMedica (NASDAQ:CALC) with a Buy rating and a price target of $22.

February 16, 2024 | 11:46 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
CalciMedica receives a Buy rating from JonesTrading with a price target of $22.
The initiation of coverage by JonesTrading with a Buy rating and a significant price target of $22 is likely to generate positive sentiment among investors, potentially driving up the stock price in the short term. Analyst ratings, especially with a Buy recommendation, can influence market perception and investor behavior, leading to increased demand for the stock.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100